Frederik Mørkeberg, Chief Executive Officer (CEO)
Frederik Mørkeberg has almost 20 years of experience from investment banking in London and Copenhagen. Frederik has extensive experience within investments and advisory as well as overseeing and understanding operational and financial risk. Frederik holds a master’s degree in Finance and Accounting (cand.merc.fir) from CBS in Copenhagen
Søren Nielsen, MD, dr.med. CSO
Søren Nielsen is an MD and has a background as professor at Aarhus University and director of a Research Center from the Danish National Research Foundation. He has published more than 400 papers and being part of pioneering aquaporin research together with Nobel Laureate professor Peter Agre, Johns Hopkins University Medical School. Søren Nielsen has received the Novo Nordisk Prize, the Biotech Builder Scandinavia Award, the EliteForsk Prize (Ministry of Research, Technology and Innovation) among others. Søren Nielsen have co-founded several companies including Action Pharma A/S (as CEO and COO) which was sold to Abbott for 600 mio DKK. Søren Nielsen is also co-founder of SynAct Pharma AB (listed), Apoglyx AB and other companies. Søren Nielsen is an investor and has been leading / co-leading the scientific and preclinical development, regulatory and clinical development of CPT.one.
Søren Nielsen, Chief Scientific Officer (CSO)
Professor, Dr.Med. Søren Nielsen, Department of Clinical Medicine, Aarhus University and is a Medical Doctor in Endocrinology.
Dr.Med. Nielsen has published a vast number of research articles and has comprehensive experience from the biotech industry where he among other has served as CEO of Action Pharma A/S, Synact Pharma Aps and 2A Pharma.
Dr. Peter Heinrich has over 20 years of experience in the pharma and biotech industry in R&D, drug development, licensing, new drug commercialization and business & corporate development and general management.
He currently serves as Chairman of BIO Deutschland, the German biotech association, and Vice Chairman of EuropaBio, the European Biotech Association.
Dr. Peter Heinrich has a PhD in biochemistry from Munich University and was a post-doc scientist at Harvard University.
He has been directly involved in start-up ventures, as well as publicly-held entities, improving shareholder value, and M&A agreements. Dr. Peter Heinrich is a serial entrepreneur, serving as a co-founder at Sinfonie Life Science Management GmbH, Co-founder and CEO of MediGene AG and co-founder of the leading immuno-oncology players Immunocore and Adaptimmune in Oxford and others.
Jette Goller Kloth is the Co-founder of CPT.one Biotech and has spearheaded the company’s early growth journey where she among other roles has served as the company’s CEO between the years 2009-2014.
She has over 25 years of experience in the field of business and clinical psychology and currently holds the position of Chief Psychologist and CEO of Acindria ApS, a company that provides services and therapeutic treatment within the field of business and clinical psychology.
Jette Goller Kloth has a M.Sc. in psychology from the University of Aarhus and systemic thinking from John F. Kennedy University, California.
Peter Popowicz is a highly experienced healthcare executive with a strong track record of delivering commercial excellence in the pharmaceutical industry, covering product launches, turnarounds and pricing and access.
He has a longstanding experience as General Manager Northern Europe for LEO Pharma, Pfizer Denmark and Sanofi Pasteur and has been Country Manager for Denmark, Sweden, Norway, Czech and Slovakia as well as leading cross-country teams.
Popowicz brings a broad experience in both mass diseases and specialized markets as well as vaccines and biological products.